Payment overview · 2025
General Payments
$105.18
6 reported records · 5 companies
Healthcare provider profile · identity verified
Jason Robert Potts, MD
Allopathic & Osteopathic Physicians|Internal Medicine · LINCOLN, NE · NPI 1215940358
Verified facts
What the public records show
CMS Open Payments records show Jason Robert Potts, MD received $105.18 in general payments during 2025 across 6 reported records.
Novo Nordisk Inc accounted for 36.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $38.82 | 36.9% | 2 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $19.86 | 18.9% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $16.55 | 15.7% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.99 | 14.2% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $14.96 | 14.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $105.18 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $21.53 | 1 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $19.86 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $19.86 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $17.29 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $17.29 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $16.55 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $14.99 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14.96 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 487 | 127 |
| Levothyroxine Sodium | Levothyroxine Sodium | 487 | 111 |
| Amlodipine Besylate | Amlodipine Besylate | 343 | 87 |
| Escitalopram Oxalate | Escitalopram Oxalate | 337 | 76 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 324 | 100 |
| Omeprazole | Omeprazole | 306 | 72 |
| Gabapentin | Gabapentin | 281 | 69 |
| Metoprolol Succinate | Metoprolol Succinate | 249 | 60 |
| Trazodone Hcl | Trazodone Hcl | 248 | 58 |
| Furosemide | Furosemide | 243 | 60 |
| Lisinopril | Lisinopril | 243 | 69 |
| Losartan Potassium | Losartan Potassium | 229 | 65 |
| Tamsulosin Hcl | Tamsulosin Hcl | 226 | 55 |
| Prednisone | Prednisone | 222 | 116 |
| Carvedilol | Carvedilol | 206 | 54 |
| Bupropion Xl | Bupropion Hcl | 194 | 36 |
| Pantoprazole Sodium | Pantoprazole Sodium | 178 | 52 |
| Duloxetine Hcl | Duloxetine Hcl | 167 | 44 |
| Metformin Hcl | Metformin Hcl | 164 | 36 |
| Tramadol Hcl | Tramadol Hcl | 162 | 36 |
| Alprazolam | Alprazolam | 144 | 33 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 133 | 38 |
| Eliquis | Apixaban | 131 | 24 |
| Hydrochlorothiazide | Hydrochlorothiazide | 131 | 33 |
| Pravastatin Sodium | Pravastatin Sodium | 131 | 32 |
| Allopurinol | Allopurinol | 129 | 34 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 127 | 28 |
| Clonazepam | Clonazepam | 126 | 16 |
| Donepezil Hcl | Donepezil Hcl | 115 | 20 |
| Metformin Hcl Er | Metformin Hcl | 115 | 29 |
| Xarelto | Rivaroxaban | 115 | 20 |
| Meloxicam | Meloxicam | 111 | 29 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 107 | 32 |
| Potassium Chloride | Potassium Chloride | 105 | 25 |
| Simvastatin | Simvastatin | 98 | 24 |
| Buspirone Hcl | Buspirone Hcl | 92 | 15 |
| Ezetimibe | Ezetimibe | 89 | 24 |
| Lorazepam | Lorazepam | 89 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 86 | 18 |
| Alendronate Sodium | Alendronate Sodium | 85 | 21 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 79 | 21 |
| Glimepiride | Glimepiride | 74 | 21 |
| Synthroid | Levothyroxine Sodium | 74 | 20 |
| Montelukast Sodium | Montelukast Sodium | 71 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 67 | 13 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 66 | 23 |
| Quetiapine Fumarate | Quetiapine Fumarate | 64 | 13 |
| Celecoxib | Celecoxib | 63 | 19 |
| Pregabalin | Pregabalin | 63 | 14 |
| Famotidine | Famotidine | 62 | 13 |
| Spironolactone | Spironolactone | 61 | 16 |
| Amoxicillin | Amoxicillin | 60 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 59 | 15 |
| Oxycodone Hcl | Oxycodone Hcl | 58 | suppressed |
| Jardiance | Empagliflozin | 55 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 54 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 51 | 12 |
| Memantine Hcl | Memantine Hcl | 50 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 50 | suppressed |
| Atenolol | Atenolol | 49 | suppressed |
| Azithromycin | Azithromycin | 49 | 44 |
| Fluticasone Propionate | Fluticasone Propionate | 49 | 17 |
| Cephalexin | Cephalexin | 48 | 34 |
| Valsartan | Valsartan | 47 | 11 |
| Farxiga | Dapagliflozin Propanediol | 46 | 11 |
| Ipratropium Bromide | Ipratropium Bromide | 45 | 17 |
| Myrbetriq | Mirabegron | 44 | 11 |
| Levetiracetam | Levetiracetam | 43 | suppressed |
| Temazepam | Temazepam | 43 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 42 | 36 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 42 | 14 |
| Lamotrigine | Lamotrigine | 41 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 40 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 37 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 37 | 34 |
| Latanoprost | Latanoprost | 37 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 36 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 36 | suppressed |
| Baclofen | Baclofen | 35 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 35 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 35 | 12 |
| Primidone | Primidone | 35 | suppressed |
| Eletriptan Hbr | Eletriptan Hydrobromide | 34 | suppressed |
| Mirtazapine | Mirtazapine | 33 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 33 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 33 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 32 | 22 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 30 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 30 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 30 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 30 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 29 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 29 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 29 | suppressed |
| Finasteride | Finasteride | 28 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 28 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 28 | 19 |
| Colchicine | Colchicine | 27 | suppressed |
| Ramipril | Ramipril | 27 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 27 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 26 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 26 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 26 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 26 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 26 | suppressed |
| Torsemide | Torsemide | 26 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 25 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 25 | suppressed |
| Verapamil Er | Verapamil Hcl | 25 | suppressed |
| Chlorthalidone | Chlorthalidone | 24 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 24 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 24 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 24 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Januvia | Sitagliptin Phosphate | 23 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 23 | 12 |
| Prazosin Hcl | Prazosin Hcl | 23 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 20 |
| Fenofibrate | Fenofibrate | 22 | suppressed |
| Methimazole | Methimazole | 22 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Estradiol | Estradiol | 21 | suppressed |
| Fentanyl | Fentanyl | 21 | suppressed |
| Novolog Flexpen | Insulin Aspart | 21 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 21 | 11 |
| Valacyclovir | Valacyclovir Hcl | 21 | 14 |
| Ranolazine Er | Ranolazine | 20 | suppressed |
| Sucralfate | Sucralfate | 20 | suppressed |
| Eszopiclone | Eszopiclone | 19 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 19 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 18 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 18 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 18 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 18 | 17 |
| Propranolol Hcl Er | Propranolol Hcl | 18 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 17 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 17 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 17 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Hydrocortisone | Hydrocortisone | 16 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 16 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 14 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 14 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 13 |
| Ozempic | Semaglutide | 14 | suppressed |
| Fluconazole | Fluconazole | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Tamoxifen Citrate | Tamoxifen Citrate | 13 | suppressed |
| Amiloride Hcl | Amiloride Hcl | 12 | suppressed |
| Clonidine | Clonidine | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 12 | suppressed |
| Mounjaro | Tirzepatide | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 12 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Creon | Lipase/Protease/Amylase | 11 | suppressed |
| Indapamide | Indapamide | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 11 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $105.18 · 6 records | Novo Nordisk Inc | EVENITY, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE, Ozempic, REXULTI, Rybelsus, Wegovy, XIFAXAN | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error